menu
    • menu
    [{"orgOrder":0,"company":"Celonic","sponsor":"Lindis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Celonic \/ Lindis Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Celonic \/ Lindis Biotech"},{"orgOrder":0,"company":"Celonic","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celonic \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Celonic \/ CureVac"},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ Intravacc"},{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Zelpultide Alpha","moa":"IL-8 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ Airway Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Celonic

    Menu

    Celonic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Lindis Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Celonic, LINDIS Biotech Sign Manufacturing Agreement for Catumaxomab

                            Details : Under the agreement, Celonic Group will leverage its expertise in GMP manufacturing to produce Removab (catumaxomab). It is being indicated for the treatment of malignant ascites in adult patients.

                            Product Name : Removab

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 19, 2025

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Lindis Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVnCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : CureVac

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Celonic and Curevac Announce Agreement to Manufacture Over 100 Million Doses of Curevac’s Covid-19 Vaccine C...

                            Details : Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.

                            Product Name : CVnCoV

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 30, 2021

                            Lead Product(s) : CVnCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : CureVac

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Intravacc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

                            Details : Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 29, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Intravacc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Celonic

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelpultide Alpha

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Airway Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus

                            Details : Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.

                            Product Name : AT-100

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 20, 2020

                            Lead Product(s) : Zelpultide Alpha

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Airway Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth